Growth & profitability
- Revenue has grown 2511.6% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
RNXT Financials RenovoRx, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$11M | 70.9% | -1114.0% | -206.0% | -138.0% | -$11M | — | $7M |
| 2024 | $43000 | -$9M | 100.0% | -25511.6% | -196.8% | -108.6% | -$9M | — | $7M |
| 2023 | — | -$10M | — | — | -341.1% | -698.0% | — | — | $1M |
| 2022 | — | -$10M | — | — | -160.5% | -136.1% | — | — | $4M |
| 2021 | — | -$6M | — | — | -41.2% | -38.8% | — | — | $15M |
| 2020 | — | -$4M | — | — | 25.9% | -198.4% | — | — | $2M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $909000 | -$3M | 84.3% | -368.4% | -32.4% | -25.4% | -$3M | — | $9M |
| Mar '26 | $563000 | -$4M | 85.1% | -616.2% | -31.3% | -25.2% | -$4M | — | $12M |
| Dec '25 | $238000 | -$3M | 88.2% | -1479.8% | -54.2% | -36.3% | -$3M | — | $7M |
| Sep '25 | $266000 | -$3M | 80.1% | -1203.0% | -36.0% | -26.0% | -$2M | — | $10M |
| Jun '25 | $422000 | -$3M | 64.0% | -634.6% | -27.2% | -21.2% | -$2M | — | $12M |
| Mar '25 | $197000 | -$2M | 52.3% | -1578.7% | -18.4% | -15.1% | -$3M | — | $15M |
| Dec '24 | — | -$3M | — | — | -64.3% | -35.5% | — | — | $7M |
| Sep '24 | — | -$2M | — | — | -34.9% | -24.6% | — | — | $10M |
| Jun '24 | — | -$2M | — | — | -25.8% | -19.9% | — | — | $12M |
| Mar '24 | — | -$1M | — | — | -60.9% | -22.5% | — | — | $4M |
| Dec '23 | — | -$3M | — | — | -107.6% | -220.1% | — | — | $1M |
| Sep '23 | — | -$1M | — | — | -23683.3% | -40.4% | — | — | $3M |
| Jun '23 | — | -$2M | — | — | -195.9% | -36.9% | — | — | $6M |
| Mar '23 | — | -$3M | — | — | -100.0% | -71.4% | — | — | $4M |
| Dec '22 | — | -$2M | — | — | -35.0% | -29.7% | — | — | $4M |
| Sep '22 | — | -$2M | — | — | -26.2% | -23.1% | — | — | $3M |
| Jun '22 | — | -$3M | — | — | -25.6% | -23.1% | — | — | $3M |
| Mar '22 | — | -$3M | — | — | -23.9% | -21.5% | — | — | $13M |
| Dec '21 | — | -$2M | — | — | -15.3% | -14.5% | — | — | $15M |
| Sep '21 | — | -$2M | — | — | -8.6% | -8.3% | — | — | $18M |
Valuation over time
How the market has priced RNXT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 1364.4× (Dec '24) to 94.0× (Sep '26).
P/S
Frequently asked questions
Is RNXT growing its revenue and profit?
Over the past 5 years, RenovoRx, Inc.'s revenue has grown 2511.6% per year. These are computed facts, not advice.
How much debt does RNXT have?
As of FY2025, RenovoRx, Inc. reported — of total debt against $7M of cash.
What is RNXT's profit margin?
In FY2025, gross margin was 70.9%, operating margin -1114.0%, and net margin -994.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.